NEUROCRINE BIOSCIENCES INC Current Assets
NEUROCRINE BIOSCIENCES INC (NBIX) had Current Assets of $1.64 billion as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-07-31
- 2026-06-30: Assets, Current $1.64B.
- 2026-03-31: Assets, Current $2.44B.
- 2025-12-31: Assets, Current $2.52B.
- 2025-09-30: Assets, Current $2.16B.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $1.64B 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $2.44B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $2.52B 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $2.16B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $1.75B 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $1.64B 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $1.72B 10-K · filed 2026-02-11 | |
| 2024-09-30 | $1.88B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $1.67B 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $1.80B 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $1.61B 10-K · filed 2025-02-10 | |
| 2023-09-30 | $1.65B 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $1.50B 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $1.43B 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $1.45B 10-K · filed 2024-02-09 | |
| 2022-09-30 | $1.21B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $1.02B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.02B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $972.80M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $1.01B 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $1.11B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $1.09B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $1.02B 10-K · filed 2022-02-11 | |
| 2020-09-30 | $1.16B 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $1.15B 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $968.20M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $831.00M 10-K · filed 2021-02-05 | $831.03M 10-K · filed 2020-02-07 |
| 2019-09-30 | $819.23M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $748.81M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $633.19M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $737.78M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $714.39M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $567.68M 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $513.72M 10-Q · filed 2018-04-30 | |
| 2017-12-31 | $554.92M 10-K · filed 2019-02-08 | |
| 2017-09-30 | $548.49M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $536.75M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $239.45M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $310.44M 10-K · filed 2018-02-13 | |
| 2016-09-30 | $357.89M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $391.97M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $400.98M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $384.07M 10-K · filed 2017-02-14 | |
| 2015-09-30 | $382.79M 10-Q · filed 2015-10-29 | |
| 2015-06-30 | $389.42M 10-Q · filed 2015-07-29 | |
| 2015-03-31 | $404.95M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $198.20M 10-K · filed 2016-02-11 | |
| 2014-09-30 | $183.87M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $197.57M 10-Q · filed 2014-08-06 | |
| 2014-03-31 | $221.74M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $148.46M 10-K · filed 2015-02-09 | |
| 2013-09-30 | $159.22M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $155.85M 10-Q · filed 2013-07-26 | |
| 2013-03-31 | $160.40M 10-Q · filed 2013-05-02 | |
| 2012-12-31 | $189.26M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $178.02M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | $181.26M 10-Q · filed 2012-07-31 | |
| 2012-03-31 | $184.97M 10-Q · filed 2012-05-02 | |
| 2011-12-31 | $132.48M 10-K · filed 2013-02-08 | |
| 2011-09-30 | $136.13M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $120.04M 10-Q · filed 2011-07-29 | |
| 2010-12-31 | $133.05M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |